TrialJournal for immunotherapy of cancer2018

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.

Joseph I Clark et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.